Y-mAbs Therapeutics (NASDAQ:YMAB) Given New $12.00 Price Target at HC Wainwright

Y-mAbs Therapeutics (NASDAQ:YMAB) had its price target dropped by HC Wainwright from $22.00 to $12.00 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s target price would indicate a potential upside of 140.00% from the stock’s current price.

Several other equities research analysts have also issued reports on the stock. Wedbush reissued an “outperform” rating and set a $23.00 target price on shares of Y-mAbs Therapeutics in a research note on Monday, March 3rd. Bank of America lowered their target price on shares of Y-mAbs Therapeutics from $14.00 to $12.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 5th. Morgan Stanley lowered their target price on shares of Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating on the stock in a research note on Wednesday, March 5th. Brookline Capital Management began coverage on shares of Y-mAbs Therapeutics in a research note on Thursday, December 5th. They set a “buy” rating and a $17.00 target price on the stock. Finally, Truist Financial lowered their target price on shares of Y-mAbs Therapeutics from $21.00 to $18.00 and set a “buy” rating on the stock in a research note on Wednesday, March 5th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, Y-mAbs Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $18.30.

Y-mAbs Therapeutics Stock Performance

NASDAQ:YMAB opened at $5.00 on Friday. Y-mAbs Therapeutics has a one year low of $4.25 and a one year high of $17.78. The firm has a market cap of $226.09 million, a price-to-earnings ratio of -9.26 and a beta of 0.65. The firm’s fifty day moving average is $5.71 and its two-hundred day moving average is $9.80.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its earnings results on Tuesday, March 4th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02). Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The firm had revenue of $26.50 million for the quarter, compared to analysts’ expectations of $26.70 million. During the same period in the previous year, the company earned ($0.02) earnings per share. As a group, equities research analysts predict that Y-mAbs Therapeutics will post -0.65 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Thomas Gad sold 10,810 shares of the business’s stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $5.23, for a total transaction of $56,536.30. Following the completion of the sale, the insider now directly owns 202,721 shares in the company, valued at approximately $1,060,230.83. The trade was a 5.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 22.50% of the stock is owned by company insiders.

Institutional Trading of Y-mAbs Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. Infinitum Asset Management LLC purchased a new stake in Y-mAbs Therapeutics in the 4th quarter valued at $1,218,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Y-mAbs Therapeutics by 17.4% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 52,356 shares of the company’s stock valued at $410,000 after buying an additional 7,765 shares in the last quarter. Two Sigma Investments LP grew its holdings in Y-mAbs Therapeutics by 31.6% in the 4th quarter. Two Sigma Investments LP now owns 88,337 shares of the company’s stock valued at $692,000 after buying an additional 21,196 shares in the last quarter. Rafferty Asset Management LLC grew its holdings in Y-mAbs Therapeutics by 17.6% in the 4th quarter. Rafferty Asset Management LLC now owns 41,255 shares of the company’s stock valued at $323,000 after buying an additional 6,178 shares in the last quarter. Finally, ProShare Advisors LLC purchased a new stake in Y-mAbs Therapeutics in the 4th quarter valued at $99,000. 70.85% of the stock is currently owned by hedge funds and other institutional investors.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.